Researchers followed 212 people with peripheral artery disease and found that those who received the blood pressure drug ramipril walked 4 minutes longer on treadmill and got an extra 75 seconds of pain-free walking, on average, than those who took placebo. The improvement may sound relatively small but it surpasses the benefits of two FDA-approved drugs intended to improve PAD patients' walking ability, a researcher said. The findings were published in the Journal of the American Medical Association.
Ramipril improves walking ability of PAD patients, study finds
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|